2026-08-252026-08-25https://scholars.csmu.edu.tw/handle/123456789/16855The compound retigabine has been targeted for use against epilepsy, migraine and neuropathic pain due to its activation of the KCNQ-channel. It activates KCNQ K+ channels by inducing a large hyper...(詳)我們已知KCNQ活化劑retigabine可以活化鉀離子通道，被認為可用來治療癲癇、偏頭痛和神經性疼痛的藥物。Retigabine 介由恆態活化曲線過極化的偏移而活化KCNQ鉀離子通道。為了探...(詳)retigabineKCNQ 活化劑突變蛋白HEK293t分子決定位retigabineKCNQ activatormutationsHEK293tmolecular determinantsresearch project